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elayed presentations of crush injury and the controversies sur-
ounding the missed compartment or wipe out syndrome
. Bridgens ∗, D.M. Crone, G. Bhatnagar, S. Owen-Johnstone
The Royal London Hospital, UK
The crush and reperfusion injury phenomenon are well
escribed. The experiences in Israel and the associated literature
arned of the consequences of performing fasciotomies in ‘missed
ompartment syndrome’ also known as ‘wipe out’ syndrome.
The high incidence of infection and increased morbid-
ty/mortality suggested a conservative, non-surgical approach to
e the preferred treatment in these cases.
However, we present two cases of crush injury which pre-
ented late and were initially thought to have wipe out syndrome,
et displayed very unusual disease progression and thus had sig-
iﬁcant delay to fasciotomy. These patients experienced ‘staged’
ompartment syndromeduring their inpatient stay andhadphased
asciotomies over a 48-h period. Both of these patients had viable
uscle at operation, suggesting that crush injury patients have a
nique disease process. Whilst the term ‘compartment syndrome’
ay actually be a misnomer in this type of injury, the consequence
f the underlying pathology is ultimately identical, even if their
resentation and pathophysiology are different.
We review the literature surrounding this subject and warn
gainst the presumption that prolonged crush injury represents a
issed opportunity.
eywords: Crush; Compartment; Delayed; Wipe-out
oi:10.1016/j.injury.2009.06.204
B.9
xposure and experience: A survey of UK Orthopaedic Trainees
xposure to limb threatening trauma
.G.P. Eardleya, D.M. Taylorb,∗, P.J. Parkerc
Northern Deanery, UK
Yorkshire Deanery, UK
Friarage Hospital, UK
im: To establish the levels of conﬁdence, exposure to caseload and
erceived adequacy of training of UK (UK) Orthopaedic Specialist
rainees in the assessment of limbviability and amputation surgery
ollowing high energy trauma.
ethods: A web-based survey was sent to a sample of orthopaedic
rainees. Scenarios included the assessment of limb viability and
mputation following signiﬁcant trauma.
Statistical analysis required 214 responses from 713 trainees to
chieve a <0.05 error rate with 90% conﬁdence. 225 responses were
eceived and analysed by means of descriptive statistics.
esults: Limb viability:
27.8% of trainees were fully conﬁdent. A positive correlation
xists between training year and fully conﬁdent reports. 68.6%
ncounter such injury either every 6 months or less frequently.
8.6% regard their training in these cases inadequate. No correlation
s seen between experience and perceived adequacy of training.
mputation:
10.3% of trainees were fully conﬁdent. A positive correlation
xists between time in training and perceived fully conﬁdent
eports.57.3% encounter such injury either every 6 months or less fre-
uently. 36.3% regard their training in these cases inadequate. No
orrelation is seen between experience and exposure to cases or
erceived adequacy of training.0 (2009) 183–235 195
Conclusion: Current training provides limited opportunities for
decision making in limb viability and amputation. Conﬁdence in
dealing with such cases is seen to increase with training. Perceived
adequacy of training and exposure to cases did not change over
time. In the light of established concerns in deﬁciencies in training
it can be seen that focussed attention should be given to complex
extremity injury as part of an educational strategy for ensuring
that future generations of orthopaedic surgeons are able to manage
complex injuries.
Keywords: Training; Limb viability; Amputation; Survey
doi:10.1016/j.injury.2009.06.205
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Pattern of tendon and nerve injuries: How accurate is pre-
operative diagnoses?
S. Venkatachalam ∗, P. Gillespie, F. Iwuawagwu
Broomﬁeld Hospital, UK
Hand injuries rank as the second most common category in A&E
medicolegal claims. Accurate diagnosis and treatment is essential,
with a high index of suspicion and low threshold for exploration.
Theﬁrst clinical examination for tendonandnerve injuries is crucial
for prioritisation in a busy unit and surgical/anaesthetic planning.
St Andrew’s centre is a tertiary level referral unit for hand
injuries and has a signiﬁcant throughput of trauma (head to feet)
with 10–15 cases daily. Most patients are reviewed in the daily con-
sultant/senior trainee-lead trauma clinic, with entries recorded on
a computerised trauma database.
We analysed the pattern of tendon and nerve injuries and accu-
racy of pre-operative assessment compared to operative ﬁndings.
The database for a 12-month period was reviewed. After exclu-
sions, 1670 sequential cases of adults with below-elbow, soft tissue
injuries and complete clinical/operative noteswere included. There
were1573 structurespotentially injured in823digits, including994
named tendons and 568 nerves. Knife and glass injuries predomi-
nated and 89% were operated on within 24h of assessment.
Anatomical accuracy was greater than 98% for both tendons and
nerves. Border nerves (index radial and little ﬁnger ulnar)were par-
ticularly at risk. Assessment of severity (nil, partial or total) was
accurate in 68% overall.
This ﬁndings support our practice of low threshold for
exploration. Distribution and accuracy by structure and zone
are discussed, with recommendations for diagnostically difﬁcult
regions.
Knowledge of potential pitfalls may prevent inappropriate
choices of anaesthetic and aids prioritisation.
Keywords: Hand; Lacerations; Tendon injuries; Nerve injuries
doi:10.1016/j.injury.2009.06.206
K1
Keynote Lecture
New technologies for the enhancement of skeletal repair
T.A. Einhorn
Boston University, USAIntroduction: The ability to stimulate fracture repair, enhance spinal
fusions, heal nonunions or restore lost segments of bone is a com-
mongoal amongorthopaedists, traumatologists, and scientistswho
investigate wound healing responses. Whilst in most clinical set-
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ings these processes are already biologically optimised, many
atients still experience delayed or impaired healing. Methods to
nsure or accelerate these healing responses are greatly needed
nd the ability to restore skeletal integrity without the morbidity
ssociated with bone graft harvesting would be a major advance in
rthopaedic surgery.
This syllabus reviews emerging pharmacological andbiotechno-
ogical methods to stimulate skeletal repair and restore lost bone. It
resents technologies available today to meet some of these chal-
enges and describes current investigations into new technologies
hat carry the promise of improving bone repair and regeneration
n the future.
iological enhancement—local
. Peptide signalling molecules
These peptide growth factors stimulate the activity of
chondroprogenitor and osteoprogenitor cells. They may also
stimulate fully differentiated chondrocytes and osteoblasts and
enhance angiogenesis. They do not induce cartilage or bone for-
mation from undifferentiated cells.
Current investigations to test the effects of these molecules
on skeletal healing responses are based on the observations that
thesemolecules areexpressedduring thenormalhealingprocess
and thus can be assumed to participate in it.
1. Fibroblast growth factor (FGF)
Fibroblast growth factor (FGF) has been shown to be
expressed during fracture healing. Investigators have shown
that an injection of -FGF or -FGF into fractures leads to
an enhancement of fracture healing. A recent study reported
that ﬁbroblast growth factor-2 in a hyaluronan gel accel-
erates fracture healing in non-human primates. Basic FGF
(4mg/ml) and hyaluronan (20mg/ml) were combined into
a viscous gel formulation and injected percutaneously into
fresh fractures. A bilateral 1mm gap osteotomy was cre-
ated in the ﬁbulae of baboons. Radiographic analysis showed
that callus area was signiﬁcantly larger at the treated sites
than in untreated sites. Load at failure and energy to failure
were signiﬁcantly increased when compared to controls. By
histological analysis, the callus size, periosteal reaction, vas-
cularity and cellularity were consistently more pronounced
in the treated osteotomies than in untreated controls. Phase
III multi-centre clinical trials on FGF-2 injections into fresh
closed tibial fractures are currently underway.
2. Vascular endothelial growth factor (VEGF)
Because of its ability to induce angiogenesis, vascular
endothelial growth factor (VEGF) has been investigated for
its potential role in the enhancement of fracture repair. In
an investigation in which mice were treated with a sol-
uble, neutralising VEGF receptor decreased angiogenesis,
decreased bone formation and decreased callus mineralisa-
tion in femoral fractureswas observed. Inhibition of VEGF also
dramatically inhibited the healing of a tibial cortical defect. In
separate experiments, exogenous VEGF enhanced blood ves-
sel formation, ossiﬁcation and callus maturation in mouse
femur fractureswhichpromotingbridgingof rabbit radial seg-
mental defects.
3. Platelet derived growth factor (PDGF)
PDGF is involved in the inﬂammatory process and is
known to induce chemotaxis and mitosis in osteoblasts. A
recombinant form, rhPDGF (Regranex gel 0.01%, Ethicon, Inc.,
Somerville, NJ), has been used with success as a topical solu-
tion in the treatment of diabetic foot ulcers. Its efﬁcacy was
shown in a study of 382 patients with type 1 or type 2 dia-
betes with chronic foot ulcers in which those patients treated
with rhPDGF the wounds healed 32% sooner than controls.
Adverse eventswere rare and similar between the twogroups.0 (2009) 183–235
A similar study showed that rhPDGF was effective in healing
foot ulcers and preventing amputation. This was a large study
including 24,898 patients with diabetic foot ulcers, of which
2394 patients received rhPDGF. The relative risk for healing
an ulcer whilst using rhPDGF was 1.32 and whilst the risk of
amputation was 0.65.
A recent study has demonstrated accelerated fracture heal-
ing in agedosteoporotic ratswithPDGF. It has alsobeen shown
that pulsed delivery of PDGF is able to simulate bone growth,
whilst constant release was inhibitory. These results indicate
that there is both an optimal concentration and time dur-
ing bone regeneration to deliver rhPDGF, and elucidating this
combination with an effective means of delivery, will likely
result in improved clinical results.
4. Prostaglandin agonists
It has been well known for many years that prostaglandin
E2 (PGE2) increases bone mass and strength when adminis-
tered systemically or locally to the skeleton. However, due to
side effects, PGE2 is considered an unacceptable therapeutic
option. Recent investigations have shown that PGE2 mitigates
its tissue-speciﬁc pharmacological activity via four different
receptors, EP1, EP2, EP3 and EP4. However, it is now known
that EP1 and EP3 mitigate the objectionable side effectswhilst
EP2 and possibly 4 are associated with bone formation. A
recently identiﬁed EP2 selective agonist has been shown to
enhance the healing of canine long bone segmental defects
and fractures without the side effects associated with admin-
istration of PGE2.Moreover, the potent anabolic activity of this
synthetic agonist may offer a therapeutic alternative for the
treatment of fractures and bone defects in patients. Further
investigation, including a clinical trial, concerning the use of
EP2 selective agonists is currently in progress.
B. Osteoinductive molecules
Deﬁnition: Osteoinduction is a phenomenon in which there is a
mitogenesis of undifferentiated perivascular mesenchymal cells
leading to the formation of osteoprogenitor cells with the capac-
ity to form new bone.
Over the past 20 years, investigators have applied the prin-
ciples of bone induction to the treatment of musculoskeletal
conditions in a variety of uncontrolled case reports or case series.
Whilst these reports have suggested the potential clinical efﬁ-
cacy of various preparations of demineralised bone matrix or
puriﬁed human bone morphogenetic proteins, only three ran-
domised clinical trials have supported the use of recombinant
bone morphogenetic proteins.
1. A prospective, randomised clinical trial involving 122 patients
with 124 tibial nonunions was conducted with the use of
rhBMP-7 (osteogenic protein-1; OP-1). All nonunions were
at least 9 months old and had shown no progress towards
healing for the 3 months prior to the enrollment of the
patient in the study. The patients were randomised to receive
either standard treatment with reduction and ﬁxation with
an intramedullarynail andautologousbone-graftingor reduc-
tionandﬁxationwithan intramedullarynail and implantation
of rhOP-1 in a type-1 collagen carrier. The results showed
that, at 9 months of follow up, 81% of 63 patients treated
with rhOP-1 and 85% of 61 patients treated with autologous
bone-grafting were judged to be healed according to clinical
criteria (p=0.524). Radiographic assessments suggested heal-
ing in 75% and 84% of these patients, respectively (p=0.218).
Although it is possible that reaming and intramedullary nail-
ing of tibial nonunions could have led to a similar rate of
healing in both groups, it was noted that prior reaming and
nailing had been performed in 54% of the OP-1 treated group
and in 44% of the autograft group. In addition, prior bone-
grafting had been performed in 43% of the patients in the
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OP-1 treated group and in 31% of the patients in the auto-
graft group. On the basis of these data, the United States Food
and Drug Administration (FDA) issued, on October 17, 2001,
a Humanitarian Device Exemption for the application of the
OP-1 implant as “an alternative to autograft in recalcitrant
long bone nonunions where use of autograft is unfeasible and
alternative treatments have failed.” A variety of regulatory
agencies in Europe, Australia, and New Zealand have also pro-
vided language permitting the use of this implant in speciﬁc
settings such as tibial nonunions ofmore general settings such
as long-bone nonunions.
2. Recombinant human BMP-2 has also been tested in clini-
cal settings, and the ﬁrst application to achieve clearance
by the FDA was for single-level interbody fusions of the
lumbar spine. On January 10, 2001, theOrthopaedic and Reha-
bilitation Devices Advisory Panel of the FDA recommended
approval of an InFUSE (Medtronic Sofamor Danek, Memphis,
Tennessee), a combination of rhBMP-2 on an absorbable col-
lagen sponge delivered in a lumbar tapered fusion device. The
dataset supporting this decision was derived from a prospec-
tive, randomised, nonblinded, 2-year multi-centre study of
279 patients with degenerative lumbar disc disease who
were randomly assigned to one of two groups that had
anterior interbody fusion with use of two tapered threaded
fusion cages. The investigational group (143patients) received
rhBMP-2 on an absorbable collagen sponge, and a control
group (136 patients) received autogenous iliac-crest bone
graft. Plain radiographs and computed tomography scans
were used to evaluate fusion at 6, 12, and 24 months after
surgery. The results showed that the mean operative time and
blood loss were less in the BMP-treated group (1.6h and the
109.8ml compared with 2.0h and 153.1ml), and the fusion
rate at 24 months was higher for the BMP-treated group com-
pared with that for controls (94.5% compared with 88.7%).
TheOwestry LowBack PainDisability scores neurologic status
improved in both groups, with similar outcomes. The control
group had eight adverse events related to the harvesting of
iliac-crest bone graft. New bone formation was noted in all
patients treated with BMP-2.
3. The most recent report on the use of BMP in the man-
agement of skeletal conditions was communicated by the
BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study
Group inDecember2002. These investigators randomised450
patients with open tibial shaft fracture to receive either ini-
tial irrigation and debridement followed by treatment with a
stoically locked intramedullary nail (so-called standard care)
or standard care and either 0.75 or 1.50mg/kg rhRMP-2 on an
absorbable collagenspongeat the timeofwoundclosure.After
12 months, there was a 44% reduction in the risk of secondary
interventions in the group treated with 1.50mg/kg rhBMP-
2 compared with that for the group treated with standard
care (relative risk =0.56 pairwise; p=0.0005). Fifty-eight per-
cent of the patients treated with 1.50mg/kg rhBMP-2 were
healed compared with only 38% in the group treated with
standard care (p=0.0008). Compared with patients treated
with standard care, those treated with 1.50mg/kg rhBMP-2
had fewer hardware failures, fewer infections, and showed
faster wound-healing.
Biological enhancement—systemic
1. Growth hormone (GH)
Growth hormone, in combination with other growth fac-tors such as insulin like growth factors, is involved in the daily
physiologic remodelling of the skeleton as well as having sig-
niﬁcant anabolic effects. Its actions are thought to be through
stimulation of osteoblastic cells and induction of angiogen-
esis. Individuals with increased production of GH, such as in0 (2009) 183–235 197
acromegaly, have increased bonemass and decreased fracture
risk. The opposite effect is seen in growth hormone deﬁcient
states.
Fracture repair in animal studies supplemented with
recombinant growth factor have shown promising results.
Yucatan mini pigs subjected to 1 cm tibial bone defects were
treatedwithdaily subcutaneous injectionsof either 100g/kg
of rhGH or saline control for 6 weeks. The treatment group
had a signiﬁcant increase in bone mineral content whilst no
difference was seen in bone mineral density. The physical
strength of the fractured bonewas also signiﬁcantly greater in
the treated animals. Both torsional failure load and torsional
stiffness were increased by 70% and 83%, respectively.
The effects of upregulation of GH are seen with an increase
in the anabolic state and result in stimulation of wound heal-
ing and preservation of lean body mass. Clinical trials have
been conducted in both trauma and post-surgical patients
using GH to attempt to modulate the catabolic state that
occurs in these situations. These studies have shown conﬂict-
ing results, but have demonstrated that GH treatment has a
low incidenceof adverse events. Recently, a large, randomised,
double-blind trial was conducted using varying concentra-
tions of growthhormone (15, 30, or 60g/kg) or placebo alone
in the treatment of open and closed tibial fractures treated
with intramedullary nail. Treatments were started within 3
days of operative ﬁxation and continued until radiographic
healing was obtained or until 16 weeks post-operatively,
whichever cameﬁrst. Results at 12monthsdidnot showapos-
itive correlation between GH treatment and time to fracture
healing. A post hoc analysis of closed tibial fractures, however,
found a signiﬁcant decrease in the time to radiographic heal-
ing in the 6-g/kg treated individuals, with fractures healing
on average at 95 days compared to 129 days in the control
group. Another important ﬁnding was that there were no dif-
ferences in major adverse events noted in this study, with
oedema and transient arthralgias being the only signiﬁcant
complaints. The positive results in close fractures will need to
be further studied, and it is likely that these and other results
will encourage further research in this area.
2. Parathyroid hormone (PTH)
Calcium homeostasis is maintained in large part due to
the effects of parathyroid hormone (PTH). When serum cal-
cium levels are low, PTH is secreted by the parathyroid gland
that then stimulates the small intestine to increase calcium
absorption, whilst suppressing calcium loss in the kidneys.
It also acts on osteoclasts, through the direct activation of
osteoblasts, to increase bone turnover and release of calcium
from the bone.
The physiological effects of continuous exposure to PTH
result in increasedbone turnover and adecrease in bonemass,
and this would not seem productive in fracture healing. Inter-
mittent dosing of PTH, however, may result in improved bone
remodelling and in increase in bone formation. Andreassen et
al. treated ratswith tibial fractureswithveryhigh intermittent
doses of either 60 or 200g/kg/day of PTH (1–34). They found
that 20 days of treatment with the higher dose resulted in an
increase in fracture callus volume and ultimate load strength
of 75% and 99%, respectively. By 40 days, load strength was
increased by 175% when compared to controls.
Recombinant human parathyroid hormone [rhPTH (1–34)]
has been approved in several countries for treating post-
menopausal osteoporosis and is marketed under the trade
name FORTEO®. Side effects have included mild increases in
serumcalcium levels, but the real concern iswith thepotential
for enhancement of tumor formation. Recent studies in rats
and mice with PTH (1–34) show the enhancement of fracture
1 xtra 4
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healing at doses comparable to those tolerated in patients. A
clinical trial on the use of PTH (1–34) to stimulate distal radial
fracture healing is currently in progress.
3. Statins
Statins (HMG-CoA reductase inhibitors) are lipid-lowering
drugs that inhibit cholesterol synthesis by blocking meval-
onic acid production. Mevalonic acid is a precursor for both
cholesterol and geranyl geranyl pyrophosphate (GGPP).Multi-
ple intracellular pathways in osteoclast depend on the actions
of GGPP, including those involved in maturation. By block-
ing these pathways, fracture repair may proceed through
increased bone formation secondary to a decrease in bone
turnover. In addition, statins have been shown to induce the
BMP promoter in bone cells.
Oral simvastatin use has been shown to increase bone min-
eral density in several human studies and subsequent animal
studies have supported these results. With regards to fracture
healing, Skoglund et al. tested simvastatin in a mouse model
of femur fractures. They produced internally stabilised femur
fractures in 81 mature BALB/c mice. Half of these mice then
received a daily oral dose of 120mg/kg of simvastatin for up
to 21 days. Their results showed that at day 14, the mechani-
cal strength of the simvastatin group was 64% greater than in
the control mice and the callus was 53% larger. Whilst their
study did not ﬁnd a continuation of these trends at 21 days,
their study demonstrated that simvastatin could be effecting
in accelerating the healing process.
The statins currently in use target the liver, and much of
the drug is metabolised (ﬁrst pass effect) and not available
for action in bone. For this reason, systemic use of statins
to target bone will require further development. In a study
to test the local application of a statin, Garrett et al. com-
bined lovastatin with biodegradable polymer nanobeads of
poly(lactic-co-glycolide acid) and injected this mixture into
femur fractures in rats. At 4 weeks, they noticed a decrease in
the fracture gap as measured by microcomputed tomography.
Clinical trials are necessary to determine if these studies will
translate into clinically signiﬁcant gains in fracture healing.
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Osteosynthesis of pilon fractures: Tips and tricks
H. Zwipp
Unfallkrankenhaus Berlin, Germany
Pilon fractures are some of the most demanding fractures of the
skeleton especially C-type fractures with additional severe soft tis-
sue injury. Our concept of operative treatment is related to both the
fracture type and the soft tissue damage. If possible B-fractures are
treated by arthroscopy and ﬂuoroscopy with reduction and percu-
taneous screw ﬁxation or anterior buttressing using small plates.
If soft tissues allow C1- and C2-fractures are treated with the AO
pilon plate, through an open anterior or medial approach. In C-type
fractures (43.C1–C3) with signiﬁcant soft tissue damage, a 2-stage
procedure with primary tibio-tarsal transﬁxation should always
be performed. After 10–12 days, secondary ﬁbula and tibia recon-
struction should be performed and ﬁxated with a pilon plate. In
cases of types II/III fractures with severe closed soft tissue injuries,
according to Tscherne, treatment should include minimally inva-
sive open reduction through limited approaches or arthroscopy
